As a further support of our results, a marked and durable response to cobimetinib was observed in the treatment of a MEK-mutated histiocytic neoplasm, even in the presence of the MEK1 p.P124L mutation [44]. Here, MAP2K1 is linked to histiocytic neoplasm.